- Home
- / Fosun Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Fosun Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.8
2024-10-29
Market Capitalization
$8.8 B
2024-10-29
Revenue
¥28.4 B
FY, 2019
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|
| Revenue | 18.4B | 24.7B | 28.4B |
| Revenue growth, % | 34.6% | 14.9% | |
| Cost of goods sold | 7.6B | 10.4B | 11.5B |
| Gross profit | 10.8B | 14.3B | 16.8B |
| Gross profit margin, % | 58.6% | 58.1% | 59.3% |
| General and administrative expense | 1.8B | 2.3B | 2.7B |
| Operating expense total | 8.7B | 12.4B | 15.0B |
| Investment income | 1.4B | 1.4B | 1.5B |
| Interest income | 79.2M | 145.7M | 186.6M |
| Interest expense | 588.7M | 937.6M | 1.1B |
| Pre tax profit | 4.1B | 3.6B | 4.5B |
| Income tax expense | 476.5M | 559.7M | 782.2M |
| Net Income | 3.6B | 3.0B | 3.7B |
| EPS | 1.3 | 1.1 | 1.3 |